SLC5A2 and diabetes mellitus: The American Diabetes Association (ADA) approved four single SGLT2 inhibitors: Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), and Ertugliflozin (Steglatro) (Simes and MacGregor, 2019).